Improvement of Abnormal Lymphocyte Responses in “Atypical” Mycobacteriosis with Indomethacin
Although chemotherapy of tuberculosis has resulted in a dramatic decrease in the number of new and active cases in the United States, relatively little improvement has been made in the treatment of diseases caused by nontuberculous mycobacteria. Depending on the type of hospital and population served by the hospital, the incidence of “atypical” mycobacteria may be as high as 30% of all mycobacterial infections (1). Aside from the clinical importance and economic consequences of these infections, these chronically ill patients provide a valuable source of new information concerning cellular defense mechanisms and resistance to chronic infectious diseases. Unlike patients with chronic fungal infections who commonly develop disease during early childhood, patients with “atypical” mycobacterial diseases are usually well during early childhood and adolescence (2). Thus, to explain the predisposition of individuals to infections with these organisms, one would predict an abnormality of immunoregulatory mechanisms rather than a failure to develop immunocompetent lymphoid cells.
KeywordsThymidine Incorporation Mycobacterial Infection Arachidonic Acid Metabolism Nontuberculous Mycobacterium Mycobacterial Disease
Unable to display preview. Download preview PDF.
- 1.Youmans, G.P. (1979). Diseases due to mycobacteria other than mycobacterium tuberculosis. In.: Tuberculosis, W. B. Saunders Co., Philadelphia.Google Scholar